Related Experiment Video
Updated: May 14, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Antihypertensive drugs and coronary artery disease : evidence from controlled trials
Paolo Verdecchia1, Fabio Angeli
1Dipartimento Malattie Cardiovascolari, Ospedale R. Silvestrini, Località Ponte della Pietra, 06100, Perugia, Italy, verdec@tin.it.
Abstract:
A reduction in blood pressure (BP) levels is the most important mechanism accounting for the reduction in cardiovascular complications induced by treatment. However, results of recent clinical trials and meta-analyses have shown that antihypertensive drugs possess important ancillary properties that might play an additional role in the prevention of cardiovascular disease.Reviewing the literature, ACE inhibitors seem to have ancillary properties that can contribute to influence the risk of coronary artery disease with mechanisms partially independent of BP reduction.On the other hand, dihydropyridine calcium channel blockers, such as amlodipine, have been proven to lower the incidence of stroke but their use seems to be effective in relieving symptoms of coronary artery disease and reducing the rate of revascularisation procedures.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Coronary Artery Disease IV: Preventive Measures
Antihypertensive Drugs: Direct Renin Inhibitors
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors